Fam-Trastuzumab Deruxtecan-nxki: HER2-Positive Cancer Treatment

Summary or Key Points

Fam-trastuzumab deruxtecan-nxki is a targeted therapy used to treat specific types of cancer, including HER2-positive breast and gastric cancers. It works by delivering chemotherapy directly to cancer cells, helping to slow or stop their growth. This HER2-targeted therapy is typically prescribed for patients whose cancer has not responded to other treatments. Always consult your healthcare provider before starting or adjusting any medication.

Names of Medication

US Brand Name: Enhertu

Generic Name: Fam-trastuzumab deruxtecan-nxki

The generic name is the scientific name of the medication, while the brand name is the name given by the manufacturer. In this article, the generic name is listed in parentheses.

Pharmacologic Category

Antibody-Drug Conjugate (ADC)

HER2-directed therapy

Dosing

Fam-trastuzumab deruxtecan-nxki is used to treat various HER2-positive cancers. The dosage depends on the specific type of cancer being treated. Always follow your doctor’s instructions and consult them before making any changes to your dose. You can also schedule a telemedicine visit with one of our providers to discuss your treatment options.

Breast Cancer (HER2-positive, metastatic or locally advanced)

Dosage: 5.4 mg/kg administered as an intravenous (IV) infusion every 3 weeks (21-day cycle).

Length of Treatment: Continue until disease progression or unacceptable toxicity.

Gastric Cancer (HER2-positive, metastatic)

Dosage: 6.4 mg/kg administered as an IV infusion every 3 weeks (21-day cycle).

Length of Treatment: Continue until disease progression or unacceptable toxicity.

Gastroesophageal Junction Cancer (HER2-positive)

Dosage: 6.4 mg/kg administered as an IV infusion every 3 weeks (21-day cycle).

Length of Treatment: Continue until disease progression or unacceptable toxicity.

Other HER2-positive Cancers (e.g., esophageal, colorectal, pancreatic, ovarian)

Dosage: 5.4 mg/kg to 6.4 mg/kg administered as an IV infusion every 3 weeks (21-day cycle), depending on the specific cancer type.

Length of Treatment: Continue until disease progression or unacceptable toxicity.

Dosage Forms and Strengths

Enhertu 100 mg powder for injection (reconstituted for IV infusion)

Administration Instructions

Fam-trastuzumab deruxtecan-nxki is administered as an intravenous (IV) infusion by a healthcare professional. The first dose typically takes 90 minutes, while subsequent doses take 30 minutes if well-tolerated. It is essential to attend all scheduled appointments for your infusions and report any side effects to your healthcare provider immediately. If you miss a dose, contact your doctor for guidance.

Adverse Reactions and Side Effects

Like all medications, fam-trastuzumab deruxtecan-nxki can cause side effects. Some are common, while others are rare but serious. It’s important to report any side effects to your healthcare provider. You can also schedule a telemedicine appointment with one of our providers to discuss any concerns.

Common Side Effects

Nausea: Feeling nauseous may occur during or after treatment.

Fatigue: Feeling unusually tired or weak is common with cancer treatments.

Hair Loss: Temporary hair thinning or loss may occur.

Decreased Appetite: You may experience a reduced desire to eat.

Serious Side Effects

Lung Problems (Interstitial Lung Disease): This can cause difficulty breathing, coughing, or chest pain. If you experience these symptoms, contact your doctor immediately.

Heart Problems: Fam-trastuzumab deruxtecan-nxki can affect heart function. Symptoms may include shortness of breath, swelling in the legs, or rapid weight gain.

Severe Allergic Reactions: Symptoms may include rash, itching, swelling, or difficulty breathing. Seek emergency medical help if these occur.

Contraindications

A contraindication is a specific situation or condition where a particular medication should not be used because it may cause harm. For fam-trastuzumab deruxtecan-nxki, there are several conditions where it is not recommended. These contraindications are important to discuss with your healthcare provider before starting treatment.

Pregnancy: This medication can harm an unborn baby. It is contraindicated in pregnant women as it may cause birth defects or miscarriage.

Severe Lung Disease: Patients with pre-existing lung conditions, such as interstitial lung disease (ILD), should not take fam-trastuzumab deruxtecan-nxki. This medication can worsen lung problems, leading to serious complications like pneumonia or respiratory failure.

Allergic Reactions: If you have had a severe allergic reaction to trastuzumab or any of the ingredients in fam-trastuzumab deruxtecan-nxki, it is contraindicated. Allergic reactions can be life-threatening, causing symptoms like difficulty breathing, swelling, or hives.

Severe Heart Conditions: Patients with severe heart problems, such as congestive heart failure, should avoid this medication. It can worsen heart function and lead to serious complications.

Always inform your healthcare provider about your full medical history before starting any new medication. If you have any of these conditions, our telemedicine providers can help you explore alternative treatment options.

Drug to Drug Interactions

Fam-trastuzumab deruxtecan-nxki can interact with other medications, potentially causing harmful side effects or reducing the effectiveness of your treatment. Below are some medications that may interact with fam-trastuzumab deruxtecan-nxki:

Anthracyclines (e.g., doxorubicin, epirubicin): These chemotherapy drugs can increase the risk of heart problems when taken with fam-trastuzumab deruxtecan-nxki.

Immunosuppressants (e.g., cyclosporine, tacrolimus): These medications can increase the risk of infections when combined with fam-trastuzumab deruxtecan-nxki, as both can weaken the immune system.

Live Vaccines (e.g., MMR, varicella): Fam-trastuzumab deruxtecan-nxki can weaken your immune system, making live vaccines less effective and increasing the risk of infection from the vaccine itself.

Be sure to inform your healthcare provider of all medications you are currently taking, including over-the-counter drugs and supplements. If you’re unsure about potential interactions, our telemedicine providers can review your medication list and offer guidance.

Fam-trastuzumab Deruxtecan-nxki in Pregnancy

Is it safe to take fam-trastuzumab deruxtecan-nxki during pregnancy? No, it is not safe to take fam-trastuzumab deruxtecan-nxki while pregnant. This HER2-targeted therapy can harm the developing baby, potentially leading to birth defects or miscarriage. If you are pregnant or planning to become pregnant, it is crucial to avoid this medication. Women of childbearing age should use effective contraception during treatment and for at least 7 months after the final dose. If you become pregnant while taking this medication, contact your healthcare provider immediately.

Fam-trastuzumab Deruxtecan-nxki while Breastfeeding

Is it safe to take fam-trastuzumab deruxtecan-nxki while breastfeeding? No, it is not recommended to take fam-trastuzumab deruxtecan-nxki while breastfeeding. Although it is unclear whether this medication passes into breast milk, there is a potential risk to the nursing infant. Women should avoid breastfeeding during treatment and for at least 7 months after the last dose. If you are currently breastfeeding or planning to breastfeed, discuss alternative options with your healthcare provider.

Estimated Cost of Fam-trastuzumab Deruxtecan-nxki

The cost of fam-trastuzumab deruxtecan-nxki can vary depending on your location and pharmacy. Without insurance, the estimated cost for a 30-day supply using a GoodRx coupon is approximately $12,000 to $15,000. Given the high price, it’s important to explore financial assistance programs or insurance coverage options. Our telemedicine providers can help guide you through these resources.

Possible Alternatives to Fam-trastuzumab Deruxtecan-nxki

Depending on your diagnosis and overall health, alternative treatments or lifestyle changes may help manage your condition. Always consult with your healthcare provider before making any changes to your treatment plan. Below are some alternatives for conditions commonly treated with fam-trastuzumab deruxtecan-nxki:

Breast Cancer (HER2-positive)

Alternatives include other HER2-targeted therapies such as trastuzumab (Herceptin) or pertuzumab (Perjeta). Hormonal therapies or chemotherapy may also be considered, depending on the stage of the cancer.

Gastric Cancer

Treatment options may include chemotherapy, radiation therapy, or other targeted therapies like ramucirumab (Cyramza). Dietary adjustments and nutritional support can also help manage symptoms and improve quality of life.

Gastroesophageal Junction Cancer

Alternatives may include surgery, radiation, or other targeted therapies such as nivolumab (Opdivo). Lifestyle changes, such as avoiding tobacco and alcohol, can also contribute to better outcomes.

Metastatic Breast Cancer

Other treatment options include hormonal therapies, chemotherapy, or immunotherapy such as pembrolizumab (Keytruda). Palliative care and symptom management are also important considerations for improving quality of life.

Locally Advanced Breast Cancer

Surgery, radiation, and chemotherapy are common alternatives. Targeted therapies like lapatinib (Tykerb) may also be considered, depending on the specific characteristics of the cancer.

Esophageal Cancer

Treatment options include surgery, chemotherapy, and radiation. Targeted therapies like trastuzumab (Herceptin) may also be used, depending on the HER2 status of the cancer.

Colorectal Cancer

Alternatives include chemotherapy, immunotherapy, and targeted therapies such as bevacizumab (Avastin). Lifestyle changes, including increasing fiber intake and engaging in regular physical activity, may also support overall health and treatment outcomes.

Pancreatic Cancer

Treatment options may include chemotherapy, radiation, or surgery. Targeted therapies like olaparib (Lynparza) may be used for patients with certain genetic mutations.

Ovarian Cancer

Alternatives include chemotherapy, surgery, and targeted therapies such as niraparib (Zejula) or bevacizumab (Avastin). Genetic testing may help guide treatment decisions and identify the most effective therapies.

For any of these conditions, it’s essential to discuss your treatment options with your healthcare provider. Our telemedicine providers are available to help you explore these alternatives and develop a personalized treatment plan.

Recent Updates on Fam-trastuzumab Deruxtecan-nxki Research

Recent research on fam-trastuzumab deruxtecan-nxki (also known as Enhertu) has shown promising results, particularly in treating HER2-positive cancers. In 2022, a study published in the New England Journal of Medicine demonstrated that fam-trastuzumab deruxtecan-nxki significantly improved survival rates in patients with HER2-positive metastatic breast cancer compared to standard chemotherapy. Ongoing clinical trials are also exploring its effectiveness in other HER2-expressing cancers, such as colorectal and pancreatic cancers.

Additionally, researchers are investigating the potential of combining fam-trastuzumab deruxtecan-nxki with other immunotherapies to enhance its effectiveness. While these studies are still in the early stages, the results so far are encouraging.

As new research continues to emerge, it’s important to stay informed about the latest developments. Our telemedicine providers can help you understand how these updates may impact your treatment plan.

James Kingsley

Learn More